Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
207
resultados
Última actualización
08/04/2026 [08:10:00]
Resumen de: AU2026202230A1
Nucleic acid constructs that allow insertion and/or expression of a sequence of interest, such as a transgene, are provided. Compositions and methods of using such constructs for expression of a polypeptide or therapeutic agent, for example, are also provided. ar a r
Resumen de: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Resumen de: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Resumen de: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Resumen de: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Resumen de: EP4721759A1
0001 A lipid nanoparticle (LNP) composition for delivering a nucleic acid drug, and a preparation method therefor and a use thereof. The composition prepared by mixing a steroid-cationic lipid compound with a helper lipid and a polyethylene glycol modified phospholipid has better stability and transfection efficiency. The use of an LNP to deliver a nucleic acid, such as mRNA, can efficiently and stably deliver a nucleic acid drug to a target cell or organ, and meanwhile, the LNP can be used for aerosol inhalation administration of the mRNA and can also be used for developing a lyophilized preparation of the mRNA. A higher specific antibody response can be induced in an experimental animal, and the compound has better safety.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP4722195A1
Provided are: a pH-sensitive cationic lipid which can be more easily synthesized through a small number of steps without requiring any organometal reaction or use of any relatively expensive starting materials; and lipid nanoparticles including the lipid. Disclosed is a pH-sensitive cationic lipid comprising a compound represented by general formula (I) or (I'), wherein R1, Z2, s, Z1, and X are as defined in the description.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: WO2024246004A1
The present invention relates to a diagnostic method (100) for diagnosing a state of a cell stack (300) of an electrochemical energy converter. The diagnostic method (100) comprises: - connecting (101) a plurality of bipolar plates (301) of the cell stack (300) to a cell voltage measurement system (311), - ascertaining (103) measurement values for each cell (303) of the plurality of cells (303) by means of the cell voltage measurement system (311), - determining (105) a characteristic value for each cell (303) of the plurality of cells (303) on the basis of measurement values ascertained by means of the cell voltage measurement system (311), - comparing (107) the characteristic value with a specified quality criterion, - outputting (109) an error message if the characteristic value does not satisfy the quality criterion, wherein the ascertaining of measurement values is carried out in a dry state of the cell stack (300).
Resumen de: WO2024246004A1
The present invention relates to a diagnostic method (100) for diagnosing a state of a cell stack (300) of an electrochemical energy converter. The diagnostic method (100) comprises: - connecting (101) a plurality of bipolar plates (301) of the cell stack (300) to a cell voltage measurement system (311), - ascertaining (103) measurement values for each cell (303) of the plurality of cells (303) by means of the cell voltage measurement system (311), - determining (105) a characteristic value for each cell (303) of the plurality of cells (303) on the basis of measurement values ascertained by means of the cell voltage measurement system (311), - comparing (107) the characteristic value with a specified quality criterion, - outputting (109) an error message if the characteristic value does not satisfy the quality criterion, wherein the ascertaining of measurement values is carried out in a dry state of the cell stack (300).
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: WO2024246004A1
The present invention relates to a diagnostic method (100) for diagnosing a state of a cell stack (300) of an electrochemical energy converter. The diagnostic method (100) comprises: - connecting (101) a plurality of bipolar plates (301) of the cell stack (300) to a cell voltage measurement system (311), - ascertaining (103) measurement values for each cell (303) of the plurality of cells (303) by means of the cell voltage measurement system (311), - determining (105) a characteristic value for each cell (303) of the plurality of cells (303) on the basis of measurement values ascertained by means of the cell voltage measurement system (311), - comparing (107) the characteristic value with a specified quality criterion, - outputting (109) an error message if the characteristic value does not satisfy the quality criterion, wherein the ascertaining of measurement values is carried out in a dry state of the cell stack (300).
Resumen de: WO2024246004A1
The present invention relates to a diagnostic method (100) for diagnosing a state of a cell stack (300) of an electrochemical energy converter. The diagnostic method (100) comprises: - connecting (101) a plurality of bipolar plates (301) of the cell stack (300) to a cell voltage measurement system (311), - ascertaining (103) measurement values for each cell (303) of the plurality of cells (303) by means of the cell voltage measurement system (311), - determining (105) a characteristic value for each cell (303) of the plurality of cells (303) on the basis of measurement values ascertained by means of the cell voltage measurement system (311), - comparing (107) the characteristic value with a specified quality criterion, - outputting (109) an error message if the characteristic value does not satisfy the quality criterion, wherein the ascertaining of measurement values is carried out in a dry state of the cell stack (300).
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: WO2024246004A1
The present invention relates to a diagnostic method (100) for diagnosing a state of a cell stack (300) of an electrochemical energy converter. The diagnostic method (100) comprises: - connecting (101) a plurality of bipolar plates (301) of the cell stack (300) to a cell voltage measurement system (311), - ascertaining (103) measurement values for each cell (303) of the plurality of cells (303) by means of the cell voltage measurement system (311), - determining (105) a characteristic value for each cell (303) of the plurality of cells (303) on the basis of measurement values ascertained by means of the cell voltage measurement system (311), - comparing (107) the characteristic value with a specified quality criterion, - outputting (109) an error message if the characteristic value does not satisfy the quality criterion, wherein the ascertaining of measurement values is carried out in a dry state of the cell stack (300).
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP4721728A1
A lipid nanoparticle composition for encapsulating a nucleic acid and a preparation method therefor. In the composition, the proportion of empty lipid nanoparticles containing no nucleic acid to the total number of lipid nanoparticles, i.e., the no-load rate, is no more than 10%. According to the preparation method, the ethanol content in the system is reduced to an acceptable level during particle fusion, so that the particles are fully fused.
Resumen de: EP4721733A1
The present disclosure relates to a nucleic acid-lipid nanoparticle composition and a lyophilized preparation thereof, and further relates to a preparation method for the composition and a use of the composition. The nucleic acid-lipid nanoparticle composition of the present disclosure comprises lactate, so that the stability of nucleic acid-lipid nanoparticles is improved in a lyophilization process and a prepared lyophilized preparation. According to the present disclosure, the total time of a freeze-drying process for the nucleic acid-lipid nanoparticles can be shortened, and energy consumption and the time cost of product scale-up production can be greatly reduced; the rehydration of lyophilized nucleic acid-lipid nanoparticles is quick, and the total amount of nucleic acids, the encapsulation efficiency, and the nucleic acid integrity are high; in addition, a lyophilized and rehydrated preparation has cell transfection efficiency not significantly different from that of a non-lyophilized nucleic acid-lipid nanoparticle stock solution, and has a high in vivo immune response, even exceeding that of the non-lyophilized nucleic acid-lipid nanoparticle stock solution.
Resumen de: CN121796624A
本发明公开了一种基于后插入法的抗体偶联脂质纳米颗粒制备方法及其应用，具体公开了一种抗体偶联核酸‑脂质纳米颗粒的制备方法，通过该制备方法制备得到的抗体偶联核酸‑脂质纳米颗粒包封率高、PDI小、偶联率高或靶向性好。
Resumen de: WO2025048714A1
There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein A comprises a carbohydrate and/or a derivative thereof; R1 and R2 are each independently a hydrophobic group; R3, R4, R5, and R6 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7, R9 and R10 are each independently optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R8 is -O-, -S-, or -NRa-, where Ra is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; m is 0 or 1; n ≥ 1; and w ≥ 1.
Resumen de: CN121796352A
本发明公开了一种PLGA‑壳聚糖纳米颗粒递送姜黄素在PC12细胞分化中的应用，具体涉及生物医学与纳米药物递送交叉技术领域，本发明通过PLGA与壳聚糖的静电相互作用制备负载姜黄素的纳米颗粒，有效解决姜黄素稳定性差、细胞摄取效率低的问题。该纳米颗粒分散均匀、尺寸均一，包封率与载药量合理，释放遵循非费克扩散过程，实现缓慢持续释放。其保留姜黄素≥70%的抗氧化活性，5‑80μg/mL浓度下对PC12细胞无毒，存活率超80%。壳聚糖修饰可增强细胞摄取能力、中和PLGA降解酸性副产物、保护姜黄素生物活性，显著促进PC12细胞神经突伸长和分支形成，为阿尔茨海默病等相关神经退行性疾病提供安全有效的新型干预手段，临床应用潜力突出。
Resumen de: CN121800969A
本发明属于医药领域，具体涉及一种纤维化微环境响应的聚合物、其制成的包载药物的纳米粒及其制备方法和用途。本发明的纤维化微环境响应的聚合物，可以作为载体包载药物并实现药物递送，其具有智能释药特性、靶向性能以及优异的安全性。采用前述聚合物与药物制成的载药纳米粒可以有效缓解器官纤维化，治疗效果显著优于游离药物，具有非常良好的临床应用前景。
Resumen de: CN121796635A
本发明涉及一种靶向共递送基因药物与免疫激动剂的脂质纳米粒及其在治疗PTEN缺失型脑胶质瘤中的应用，通过设计构建糖基化聚乙二醇脂质化合物DMG‑PEG‑Glu，与可电离脂质、胆固醇和辅助脂质制得以葡萄糖（配体）修饰的脑靶向共递送PTEN mRNA（基因药物）和cGAMP（免疫激动剂）的脂质纳米粒CP‑GLNPs。本发明首次实现了PTEN mRNA和cGAMP的LNP共递送，且尺寸在百纳米级别，有利于借助脑内皮细胞及肿瘤细胞表面高表达的葡萄糖转运蛋白1高效通过血脑屏障进入脑部发挥作用。本发明实现了核酸药物和免疫激动剂共递送技术的突破，是基因治疗与免疫治疗标本兼治的新型纳米药物递送系统。
Resumen de: CN121796378A
本发明属于生物医药技术领域，公开了适配体修饰的红细胞膜伪装纳米粒及其制备方法和应用，具体包括纳米粒，包裹在纳米粒表面的红细胞膜，以及与所述红细胞膜连接的适配体；所述适配体为AS1411；所述纳米粒包括聚乳酸‑羟基乙酸共聚物。本发明提出了适配体修饰的红细胞膜伪装纳米粒及其制备方法和应用，具有红细胞膜的长循环特性、AS1411适配体的高效主动靶向能力以及诊疗一体化功能，实现了药物的高效靶向递送与成像同步，具有毒副作用小、治疗效果好的优点，可用于制备肿瘤靶向诊疗一体化药物，具有良好的临床转化前景。
Resumen de: CN121796584A
本发明涉及生物医药和纳米材料领域，具体是一种可靶向肿瘤并用于光热治疗与免疫治疗联合的巨噬细胞膜包被的pH响应性仿生纳米粒子及其制备方法与应用。本发明的仿生纳米药物递送系统可特异性靶向肿瘤细胞与组织，延长药物在膀胱内的滞留时间，提升抗肿瘤疗效，增强全身免疫激活，并减少不良反应，有效抑制肿瘤转移和复发，展现出良好的临床应用潜力。
Resumen de: CN121796347A
本发明提供了一种基于阳离子脂肽的肺靶向脂质纳米颗粒(LNP)及其制备方法与应用。所述肺靶向LNP由阳离子脂肽、DLin MC3‑DMA、胆固醇和DMG‑PEG 2000组成，能够通过静电相互作用高效包封并压缩核酸，从而获得较高的核酸包封率。基于阳离子脂肽所携带的正电荷，所述LNP能够在血浆中吸附特定生物分子，形成蛋白冠结构，利用该电晕效应促进LNP的肺细胞内吞作用，实现对肺部的高效主动靶向。本发明的LNP能够特异性递送核酸至肺部，并支持稳定的基因表达，适用于肺部相关疾病的治疗。与现有的SORT LNP技术相比，本发明无需额外添加大量阳离子脂肽，总脂质用量较低，展现出更好的生物相容性和安全性。
Resumen de: CN121796349A
本发明提供了一种具有靶向M2型肿瘤相关巨噬细胞功能的脂质纳米颗粒及其制备方法和应用，涉及生物技术领域。本发明提供的具有靶向M2型肿瘤相关巨噬细胞功能的脂质纳米颗粒，以磷酸锰为内核，一方面，具有良好的生物相容性和稳定性，能够保护mRNA免受生物体内的降解，提高负载核酸的递送效率；另一方面，能够激活免疫效应，诱导DNA损伤，激活cGAS‑STING信号通路，增效免疫治疗。脂质纳米颗粒中RP182肽与白蛋白通过二硫键偶联，在肿瘤微环境中二硫键会发生断裂暴露RP182肽，实现对M2型肿瘤相关巨噬细胞的靶向。
Resumen de: CN121796348A
本发明提供了一种防治鸡球虫病的中药纳米粒及其制备方法和应用，涉及中兽药技术领域，包括药物组份与响应载体；其中，药物组份由第一煎剂与第二煎剂构成，第一煎剂由黄芪与白术煎制获得，第二煎剂由常山与青蒿煎制获得，二者经分别合并煎液并浓缩后按预设比例形成统一药物组份；响应载体包括琥珀酰化壳聚糖以及含偶氮键的偶氮苯衍生物交联聚合物，药物组份被包埋于响应载体中形成核壳构型的中药纳米粒；通过琥珀酰化壳聚糖在酸性环境下发生溶胀以及偶氮键在偶氮还原酶作用下发生结构变化，使中药纳米粒在鸡球虫病相关肠道环境中更易释放药物组份；本发明还提供中药纳米粒的制备方法以及其在制备防治鸡球虫病的兽药制剂或饲料添加剂中的应用。
Resumen de: CN121796346A
本发明属于肿瘤治疗技术领域，尤其涉及一种金属多酚网络包被的载药介孔有机硅纳米粒及其制备方法和应用，先通过胶束/前体共模版组装法制备介孔有机硅纳米粒（MON），然后进一步地对其进行氨基化修饰、羧基化修饰、共载药物，最后加入铜盐溶液和单宁酸（TA）溶液混合后进行配位络合反应，最后加入透明质酸（HA）进行修饰制备得到，利用本发明方法得到的DQMCTH纳米粒呈类球形，形态规则、分布均匀，无明显的树枝状分支和中心辐射状孔道，本发明方法能够有效荷载药物，并被MPN有效保护和HA靶向修饰；更重要的是，本发明方法制备的DQMCTH纳米粒显示出pH/GSH/HAase三重敏感的药物释放，细胞和动物实验结果表明，本发明方法制备的DQMCTH纳米粒对耐药性乳腺癌模型具有较高的抗肿瘤活性。
Resumen de: CN121796351A
本发明公开了一种基于脂质体‑多糖复合材料的亚麻木酚素新型递送体系及其制备方法，涉及生物材料技术领域。包括亚麻木酚素和脂质体‑多糖复合材料，亚麻木酚素和脂质体‑多糖复合材料通过搅拌均匀、稀释、超声破碎得到逐层包裹递送体系；脂质体‑多糖复合材料包括蛋黄卵磷脂与甘油制备的纳米脂质体和壳聚糖与海藻酸钠复合的多糖层；蛋黄卵磷脂与甘油通过搅拌均匀、稀释、超声破碎得到的纳米脂质体，蛋黄卵磷脂、甘油和亚麻木酚素的混合质量比例为8：1：0.1；壳聚糖与蛋黄卵磷脂、甘油和亚麻木酚素的混合液添加比例为1：1；壳聚糖与海藻酸钠混合体积比为：1：2。本发明提供了一种包封率高，高效、稳定与靶向递送的亚麻木酚素新型递送体系及其制备方法。
Resumen de: CN121796587A
本发明公开了一种声敏仿生纳米药物及其制备方法，其属于生物医药技术领域。本发明的声敏仿生纳米药物包括卟啉杂化的中空介孔有机二氧化硅、巨噬细胞膜以及胆固醇代谢调控药物，所述卟啉杂化的中空介孔有机二氧化硅既是声敏剂也是载体，所述巨噬细胞膜涂覆于中空介孔有机二氧化硅外层表面，中空介孔有机二氧化硅骨架上杂化有声敏剂中四（4‑羧基苯基）卟啉（TCPP），其介孔及中空结构上负载有Ava，其通过调控肿瘤细胞与T细胞胆固醇代谢并协同SDT来提高肿瘤的杀伤效果。且所述声敏仿生纳米药物通过“代谢‑声动力‑免疫”多维度联合为肿瘤治疗提供了新范式，突破了传统单一治疗的局限性。
Resumen de: CN121796589A
本发明公开了一种肿瘤细胞外泌体模拟纳米声敏剂及其制备方法与应用，属于肿瘤治疗技术领域。所述纳米声敏剂由MnCO3颗粒、BPTES及外泌体膜复合构成，外泌体膜表面含有的CD63蛋白可与肿瘤细胞表面过表达的CD9受体特异性结合，实现肿瘤靶向递送。所述纳米声敏剂在超声照射触发下可释放MnCO3与BPTES：其中MnCO3兼具声敏剂功能，可产生活性氧核心成分单线态氧，同时通过类过氧化物酶活性催化肿瘤微环境中的H2O2生成·OH；而BPTES可抑制谷氨酰胺酶活性，阻断谷胱甘肽合成通路，进而削弱GSH对活性氧的清除能力，显著增强活性氧的肿瘤杀伤效能。本发明为肿瘤精准治疗提供了全新的技术方案与策略支撑。
Resumen de: CN121796609A
本发明属于生物医药技术领域，公开了涉及一种阳离子聚合物靶向纳米材料修饰的siRNA纳米药物及其应用。本发明siRNA纳米药物具有有效的穿透血脑屏障，增加siRNA药物脑组织分布的能力。
Resumen de: CN121796420A
本发明属于特殊医学用途配方食品技术领域，尤其涉及一种用于治疗阿尔兹海默症的脂肪组件及其制备方法。制备所述脂肪组件的原料包括按重量份数计算的以下组分：中链甘油三酯、淀粉糖、二氧化硅、酪蛋白酸钠、辛烯基琥珀酸淀粉钠、单，双甘油脂肪酸酯、氢氧化钾；以及神经保护性营养素组合。本发明创造性地将快速供能的中链甘油三酯与具有特定机制的神经保护营养素相结合。中链甘油三酯提供高效的酮体能源；柠檬酸镁稳定神经元兴奋性；烟酰胺核糖支持细胞能量代谢；ω‑3脂肪酸则发挥抗炎和修复神经细胞膜的作用。四种成分从能量供应、神经元稳定、代谢支持和结构修复提供保护，在控制阿尔兹海默症的同时，带来更好的神经功能预后。
Resumen de: CN121796350A
本发明公开了一种磁性纳米粒子材料及其制备方法和应用，涉及医药领域。本发明选择柠檬酸修饰的磁性纳米粒子作为载体，通过在其表面共价偶联双氨基聚乙二醇作为桥梁分子，实现了多肽药物（如特立帕肽）与磁性纳米粒子的高效、定向偶联，显著提高了药物负载效率、生物相容性和磁靶向能力，且全程水相反应，避免了有机溶剂使用，保持了药物的高生物活性，为多肽药物的高效制备提供了新的途径。
Resumen de: CN121800672A
本发明公开了螺环氨基脂质化合物及其制备方法和应用，具有以下结构式（I）所示螺环氨基脂质化合物或其药学上可接受的盐、立体异构体，以及其作为用于递送治疗剂的脂质纳米颗粒制剂制备方法和用途。。
Resumen de: CN121796631A
本发明提供了一种抗炎和抑制心肌细胞铜死亡的载药纳米马达，纳米马达由由evolocumab‑PEG‑DSPE纳米颗粒与CuxO@GSNO脂质体的自组装形成CuxO@GSNO‑evolocumab；本发明提供了通过研究表明CuxO@GSNO‑evolocumab通过双重靶向来治疗AMI，其一方面通过调控炎症相关通路，抑制AMI后的炎症反应；另一方面通过调控自噬通路，干预铜死亡过程，最终实现对心肌细胞的保护、改善心功能。
Resumen de: CN121796620A
本发明涉及生物医药领域，具体涉及一种AS易损斑块治疗纳米粒、制备方法及应用，纳米粒，包括中空介孔的二氧化锰纳米球，二氧化锰纳米球负载5α‑羟基木香酸及全氟戊烷；二氧化锰纳米球外覆M2型巨噬细胞‑脂质体杂化膜，M2型巨噬细胞‑脂质体杂化膜上表达有VLA‑4。通过本申请方案，实现了斑块内新生血管的正常化，进而稳定斑块，解决了现有技术中无法从新生血管的正常化角度进行治疗的问题。
Resumen de: CN121800865A
本发明公开了安全高效的肽基可离子化脂质及其制备方法与应用。所述肽基可离子化脂质为式II所示的化合物，式II中n为1‑7的整数。基于式II所示的化合物制备的 LNP在疗效、安全性与器官特异性间达成了协同平衡，作为下一代肝脏PILOT递送平台，为临床可转化的mRNA疗法提供了关键支撑。
Resumen de: CN121796574A
本发明公开了免疫激动剂及其制备方法，涉及免疫激动剂制备技术领域，所述免疫激动剂的制备方法包括以下具体步骤：S1、双靶点免疫激动剂单体制备；S2、阳离子脂质体内核制备；S3、仿生细胞膜包被和S4、成品检测。该免疫激动剂及其制备方法，配置过程中用连续流微反应器两步合成双靶点单体，通过分段精准控温的方式搭配微波强化，能够缩短反应周期，利用微反应技术实现激动剂的高效包载，避免传统批次法包封率低、粒径不均的问题,此外MDC细胞膜提取经差速离心有利于保障膜完整性，其表面CD11c标志物实现利用细胞仿生膜实现主动靶向，3:1体积比的脂质体与膜囊泡融合后，体外BMDC结合率较裸脂质体提升。
Resumen de: CN119462842A
The invention belongs to the field of biological medicines, and particularly relates to affinity peptides targeting CD47 and M2 type macrophages. The amino acid sequence of the CD47 affinity peptide is shown as SEQ ID NO: 1, and the amino acid sequence of the M2 type macrophage targeting peptide is shown as SEQ ID NO: 2. The invention also relates to preparation and application of the protein. The preparation comprises the following steps: forming a dual-targeting peptide and a transmembrane fusion protein; the molecules are expressed and synthesized by using nucleic acid molecules, and particularly a polypeptide expression and nano delivery system based on an engineered cell membrane is designed. The molecule provided by the invention can be compatible with CD47 and M2 type macrophage affinity peptide, and after a nano-carrier is designed to be combined with an STING agonist, M2 type macrophages are reprogrammed, so that the anti-tumor immune response is further enhanced.
Resumen de: WO2024263770A1
The present disclosure relates to lipidoid compounds comprising toll-like receptor (TLR) agonists, lipid nanoparticles (LNPs) comprising the same, and methods of use thereof. In certain embodiments, the LNPs described herein are useful for enhancing the therapeutic and/or prophylactic effect of vaccine compositions.
Resumen de: CN121226194A
Provided herein are lipid compounds, such as compounds of Formula (I). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, such as a compound of Formula (I).
Resumen de: CN121796588A
本发明涉及抗菌材料技术领域，提供一种近红外光热酶三重响应协同抗菌纳米复合材料及制备方法，包括：（1）以具有近红外二区吸收的硫化铜纳米片为结构基元，通过连续水热法，依次在其表面构筑介孔二氧化硅隔离层和钨酸铋量子点外延层，形成具有Z‑scheme能带结构的核‑壳‑卫星异质结；（2）将天然抗菌酶与具有类过氧化物酶活性的过渡金属单原子纳米酶，通过共价偶联剂在异质结的介孔通道内进行定向组装，构建级联催化系统；（3）以异质结为载体，在低温、惰性氛围及预设波长可见光引发条件下，通过表面引发可控自由基聚合，在材料表面生长具有低临界溶解温度的热响应性聚合物壳层；本发明能较佳地协同抗菌。
Resumen de: CN121775082A
本发明提出了一种改善精神障碍组合物及其制备方法，属于医药技术领域。将铁皮石斛、茯苓、大枣、五味子经过水提醇沉，得到水提中药多糖，滤液干燥得到水提取物，滤渣经过发酵，分别得到益生菌液、发酵中药多糖和发酵提取物，将发酵中药多糖包埋褪黑素、帕罗西汀后经过疏水改性，制得疏水改性包埋颗粒，将水提中药多糖羧基化，包埋益生菌得到益生菌包埋微球，与疏水改性包埋颗粒、水提取物和发酵提取物混合均匀，制得改善精神障碍组合物，具有很好的改善精神障碍、调节睡眠，改善抑郁等症状，也通过脑‑肠轴改善人的精神状态和情绪状况，中药滋阴调节人体状态，提高患者的依从性，提高药效的同时，降低了药物的成本。
Resumen de: KR20250036032A
The nucleic acid transfer complex is the helper lipid of 20 parts by weight to 5, the ionizable lipid of 40 parts by weight to 20, the cationic lipid of 30 parts by weight to 10, 0. Lipid nanoparticles including 5 to 3 parts by weight of polyethylene glycol lipid (lipid-anchored peg) and 30 to 50 parts by weight of cholesterol; and nucleic acids collected inside the lipid nanoparticles. The nucleic acid delivery complex of the present invention efficiently delivers nucleic acids to cells and gram-negative bacteria, thereby enabling the regulation and editing of gene expression.
Resumen de: CN121774915A
本发明公开了靶向ACKR3的巨噬细胞膜纳米粒及其在脂肪肝IRI中的应用，涉及生物医药和纳米技术领域；其制备方法包括：使用LPS预刺激巨噬细胞24h后使之发生极化并提取巨噬细胞膜，再使用巨噬细胞膜包被负载shACKR3的纳米颗粒得到LPS‑MM/PLGA‑shACKR3；以聚乳酸‑羟基乙酸共聚物PLGA作为纳米载体，负载具有特异性启动子的ACKR3‑shRNA质粒，制备得到纳米颗粒PLGA‑shACKR3；然后将LPS预刺激的巨噬细胞膜包被于PLGA‑shACKR3纳米颗粒表面，即得。本发明实现病变部位的主动靶向和高效蓄积。
Resumen de: CN121774877A
一种环境响应型可注射复合水凝胶及其制备方法与应用，属于生物医用材料技术领域。为解决利用黄芪甲苷治疗动物骨关节炎（OA）生物利用度低及可注射水凝胶在治疗OA时功能单一、载药与释药效率有待提升等技术问题，本发明利用物理‑化学双交联原理，使改性的HA和COS发生席夫碱化学反应，形成第一网络结构；使改性HA、SA、COS与PDA生成多种物理交联反应，形成第二网络结构；以关节腔中钙离子作为引发剂，与SA发生离子交联，形成环境触发的水凝胶第三网络结构，从而构建得到具有多重网络结构的复合水凝胶。本发明制备的可注射复合水凝胶对OA表现出显著治疗效果，对于推进OA的临床治疗具有重大的理论意义和实际应用价值。
Resumen de: CN121774912A
本发明提供了一种提升姜黄素和胡椒碱稳定性和生物利用度的复合颗粒及其制备方法，属于营养活性成分递送体系技术领域。本发明以卡拉胶、胡椒碱和壳聚糖为原料，使用反溶剂共沉淀法和逐层组装技术，将姜黄素和胡椒碱共载于姜黄素‑玉米醇溶蛋白‑卡拉胶‑胡椒碱‑壳聚糖复合颗粒中。与游离姜黄素和胡椒碱相比，本发明构建的层层结构复合颗粒作为姜黄素和胡椒碱的共包埋递送载体，不仅可以增加姜黄素和胡椒碱的理化稳定性，还显著提高了姜黄素和胡椒碱的生物活性和效能，显著延长了姜黄素和胡椒碱的体内滞留时间，提高生物利用度。
Resumen de: US2025241860A1
A hollow multilayer MOF material and its preparation method and application relates to the field of nano drug delivery therapy technology. A ZIF-67@ZIF-8@ZIF-67@ZIF-8 hollow multilayer MOF material is applied as a thrombus drug nanocarrier to prepare drugs for thrombus treatment. In vitro experiments indicate that the thrombus drug nanocarrier has an efficient targeting effect and an excellent sustained release effect in combination with streptokinase and warfarin, and the thrombus drug nanocarrier has a good therapeutic effect and the long-term anticoagulant effect.
Resumen de: CN121782826A
本发明公开了一种mRNA‑LNP制剂及其冻干方法，冻干方法包括如下步骤：取mRNA‑LNP纳米颗粒和冻干保护剂组合物混合，得到混合物：将混合物先进行预冻，得到冻结体；在低于冻结体共晶点温度的条件下，将冻结体进行升华干燥，得到初产物；将初产物进行解析干燥，得到mRNA‑LNP制剂。本发明采用超低温预冻、缓慢解析干燥、低温终点冻干曲线制备出稳定的纳米粒径、相当高的核酸包封率及其生物活性的mRNA‑LNP样品，该mRNA‑LNP样品可在常温下长时间保存。
Resumen de: CN121780566A
本申请公开了一种RNA及含有RNA的药物，所述RNA包含开放阅读框(ORF)，所述开放阅读框(ORF)编码O‑GlcNAc糖基转移酶OGT或O‑GlcNAc糖苷水解酶OGA。本申请还提供一种含有药物组合物、蛋白、DNA分子、重组质粒、RNA药物及其用途。在本申请提供的RNA，通过载体进行递送，所述RNA在体内利用自身的原料和翻译机制合成O‑GlcNAc糖基转移酶OGT或O‑GlcNAc糖苷水解酶OGA，从而实现O‑GlcNAc糖基转移酶OGT或O‑GlcNAc糖苷水解酶OGA对体内靶蛋白糖的修饰作用。
Resumen de: CN121774917A
本发明涉及新型纳米材料技术领域，公开了一种负载卡巴他赛的pH/ROS双响应性纳米材料及其制备方法与应用，该纳米材料以pH/ROS双响应材料为载体，载体上负载有卡巴他赛，pH/ROS双响应材料由环糊精与肉桂醛主要成分CA、HPAP偶联合成。本发明体外和体内实验表明，CBZ/FA‑CA‑OCD NPs能够富集于肿瘤组织，并通过FA介导的内吞作用被PC‑3和LNCaP细胞摄取。这些富集的纳米颗粒在酸性微环境和/或高活性氧微环境中可迅速释放卡巴他赛，进而有效抑制前列腺癌的生长。将CBZ/FA‑CA‑OCD NPs与抗PD‑1抗体联合使用，可显著增加CD8+和CD4+T细胞的浸润，逆转前列腺癌的免疫抑制微环境，并明显抑制肿瘤生长。本发明为调控肠道菌群以提高前列腺癌化疗免疫联合疗法的有效性提供了一种极具前景的策略。
Resumen de: CN121774910A
本发明涉及药物制剂技术领域，具体公开了一种牛血清白蛋白包普鲁士蓝载药纳米粒及其制备方法和用途，所述载药纳米粒为牛血清白蛋白包普鲁士蓝载药纳米粒，是将姜黄素(Curcumin，Cur)通过疏水作用共载到普鲁士蓝表面获得。本发明提供的载药纳米粒能显著提高药物在动脉粥样硬化微环境中积累和保留时间。静脉注射给药后可以实现被动靶向，在炎症部位释放出普鲁士蓝和姜黄素，普鲁士蓝凭借本身的类酶活性清除炎症部位的活性氧，并且辅以808纳米激光照射，普鲁士蓝发挥光热效应增加泡沫细胞内脂质的外排，联合姜黄素的抗炎特性，提高治疗效果。
Resumen de: CN121775000A
本发明属于生物医药领域，涉及NR1D1抑制剂在制备用于治疗脓毒症的药物中的用途，该NR1D1抑制剂包含能特异性靶向沉默NR1D1基因的siRNA，能够上调BMAL1并恢复IGF2BP2‑ ATP6V1B2/ATP6V0c轴，显著改善脓毒症免疫抑制及继发感染防御。
Resumen de: CN121774913A
本发明公开了一种具有类风湿性关节炎关节腔微环境调控功能的纳米药物复合材料及其制备方法与应用。所述纳米药物复合材料包含：碳酸钙纳米颗粒；包覆在碳酸钙纳米颗粒表面的单宁酸；和促生物相容物质。本发明的纳米药物复合材料通过局部关节腔注射，可以在关节腔内滞留一定时间，并且通过代谢循环逐渐离开关节腔。该纳米药物复合材料在类风湿性关节炎的关节腔内可实现快速的酸中和，并减轻微环境的氧化应激。通过酸中和与抗氧化的联合作用，利用碳酸钙和单宁酸的协同增效作用，可以有效逆转微环境内具有保护作用的M2巨噬细胞的脂质过氧化，减少M2巨噬细胞铁死亡，从而增强抗炎作用，缓解类风湿性关节炎的进展。
Resumen de: CN121774911A
本发明公开了一种多层聚合物功能化的植物源纳米递送系统及其制备方法，包括：(a) 一个植物源外泌体样纳米囊泡核心；(b) 一种包载于所述植物源外泌体样纳米囊泡核心内或与其结合的生物活性物质；及(c) 一个包覆所述植物源外泌体样纳米囊泡核心的多层聚合物壳层，所述壳层包括至少一个阳离子聚合物层和至少一个阴离子聚合物层。该系统显著提升PDEV载体在模拟胃酸、消化酶及长期储存条件下的物理和化学稳定性，防止纳米颗粒聚集和活性物质过早泄漏。通过表面修饰增强纳米系统与肠道上皮细胞的相互作用，提高细胞摄取效率和跨上皮屏障的转运能力。
Resumen de: CN121774914A
本发明公开了一种用于深层肿瘤穿透的锥状非对称纳米机器人及其制备方法和应用，该非对称纳米机器人的结构为Fe3O4@mPDA@MnO2&mSiO2，记为FPM&S；FPM&S纳米机器人为非对称结构的纳米颗粒，非对称结构中一端为核壳结构，其中，核为球形Fe3O4，壳为介孔聚多巴胺颗粒；另一端为棒状介孔SiO2，且棒状结构远离Fe3O4的一端呈锥状；在介孔聚多巴胺表面负载有MnO2；本发明通过构建具有锥状尾部的非对称结构，提高了纳米机器人在运动过程中的前向楔入能力，从根本上改善深层肿瘤穿透性能；通过同一纳米机器人实现了光热‑芬顿‑GSH耗竭多机制在空间与时间上的协同治疗，提高了肿瘤深层区域的整体治疗效率，解决了现有非对称微/纳米机器人在肿瘤深层穿透能力不足、治疗模块协同效率有限等问题。
Resumen de: CN121775134A
本发明公开磁电纳米颗粒协同交变磁场系统在制备治疗牙周炎条件下牙周组织再生的修复产品中的应用，其中该磁电纳米颗粒包括具有压电性能的壳结构和具有磁电响应性能的核结构，该磁场系统为外加交变磁场。本发明采用水热法和溶胶‑凝胶法制备了具有核壳结构的磁电纳米颗粒，其具有较高的生物相容性和安全性。本发明进一步通过体内实验验证了其治疗效果，结果表明，磁电纳米颗粒协同交变磁场系统能够用于治疗牙周炎条件下牙周组织再生。此外，该外加交变磁场参数低频温和而有效，当前磁电纳米颗粒研究趋势常采用更高强度进行全身或深部组织应用，而本发明证明了即使低强度低频刺激也足以对牙周炎产生有效的治疗效果，这对临床牙科治疗中患者的舒适度与安全性具有重要优势。
Resumen de: WO2024246004A1
The present invention relates to a diagnostic method (100) for diagnosing a state of a cell stack (300) of an electrochemical energy converter. The diagnostic method (100) comprises: - connecting (101) a plurality of bipolar plates (301) of the cell stack (300) to a cell voltage measurement system (311), - ascertaining (103) measurement values for each cell (303) of the plurality of cells (303) by means of the cell voltage measurement system (311), - determining (105) a characteristic value for each cell (303) of the plurality of cells (303) on the basis of measurement values ascertained by means of the cell voltage measurement system (311), - comparing (107) the characteristic value with a specified quality criterion, - outputting (109) an error message if the characteristic value does not satisfy the quality criterion, wherein the ascertaining of measurement values is carried out in a dry state of the cell stack (300).
Resumen de: US2025346925A1
Provided nucleic acid-based expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, within a target cell, including a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell. Also provided are formulations and systems, including fusogenic lipid nanoparticle (LNP) formulations and systems, for the delivery of nucleic acid-based expression constructs as well as methods for making and using such nucleic acid-based expression constructs, formulations, and systems for reducing, preventing, and/or eliminating the growth and/or survival of a cell, such as a senescent cell and/or a cancer cell, which is associated with aging, disease, or other condition as well as methods for the treatment of aging, disease, or other conditions by the in vivo administration of a formulation, such as a fusogenic LPN formulation, comprising an expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, in a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell.
Resumen de: CN121774916A
本发明公开了一种索拉非尼协同四氧化三铁强化铁死亡的仿生纳米平台及其制备方法，所述仿生纳米平台包括SF/Fe3O4@PMO@MM纳米颗粒，所述SF/Fe3O4@PMO@MM纳米颗粒由内而外依次包括核心、壳层和膜层；其中，所述核心包括Fe3O4纳米颗粒；所述壳层包括包覆在所述核心表面的介孔有机硅层，所述介孔有机硅层与核心构成Fe3O4@PMO纳米颗粒，且所述介孔有机硅层的介孔内负载有索拉非尼（SF）；所述膜层包括包覆在所述壳层表面的巨噬细胞膜（MM）。本发明的纳米平台能够在肿瘤组织中通过级联反应高效生成活性氧（ROS）并协同索拉非尼诱导肿瘤细胞发生铁死亡，通过靶向肿瘤实现对肿瘤细胞的选择性杀伤，具有主动靶向、免疫逃逸、微环境响应及协同治疗功能。
Resumen de: AU2024328597A1
In some aspects, the present disclosure provides methods for generating CAR T cells in situ. The present disclosure provides lipid nanoparticles that selectively target a spleen cell, in particular, a lymphocyte such as a T cell. The lipid nanoparticle provided herein contain a five component composition that includes a permanently anionic lipid giving the lipid nanoparticle an apparent pKa of less than 6.
Resumen de: US20260092293A1
This application relates to an engineered RNA molecule, a DNA molecule encoding the engineered RNA molecule, and use of the engineered RNA molecule. The engineered RNA molecule comprises a Poly(A) tail sequence containing an miRNA binding site. The Poly(A) tail enables the accurate expression of a target gene in an organ, a tissue and/or a cell.
Resumen de: WO2026069376A1
The present invention provides a topical aqueous nano-dispersion composition comprising at least one antifungal agent and lipid carrier particles, wherein the at least one antifungal agent is entrapped within the lipid carrier particles in molecular form. The nano-dispersion has drug entrapment efficiency in the range of 70 to 97%. The present invention further provides process of preparing the composition, method of treating/preventing a fungal infection and use thereof.
Resumen de: WO2026073053A1
Provided is a nanoparticle vaccine delivery7 platform that simultaneously co-delivers MHC class I and II restricted antigens and an adjuvant. Also provided is the use of the nanoparticle vaccine delivery platform to is elicit a targeted immune response in a subject having or suspected of having or suspected of having cancer, an autoimmune disease, or an autoimmune state. Additionally provided are methods for immunizing a subject having or suspected of having a cancer, an autoimmune disease, or an autoimmune state with the nanoparticle vaccine delivery platform.
Resumen de: WO2026068222A1
Provided herein are embodiments of composition that include one or more particulates. Several embodiments provide one or more particulates that include one or more lipid nanoparticles coated in an excipient matrix, and encapsulating at least one pharmaceutically active ingredient. Several embodiments provide for particulates that at least partially encapsulate the pharmaceutically active ingredient and the excipient matrix that at least partially cover the outside of the particulates.
Resumen de: WO2026068294A1
What is described herein relates to a method for generating micro-particles comprising the steps of providing an aqueous nanosuspension comprising nanoparticles as seeding material characterized by a nano-particle size in at least one of length, diameter or height of a d90 in the range of 10 nm and 999 nm as measured by Dynamic Light Scattering (DLS), laser diffraction or electron microscopy and at least one stabilizer, providing a homogenous saturated solution of a substance in a crystallization medium where said substance is the same substance as the substance constituting the nanoparticles in the nanosuspension mixing the homogenous saturated solution and the aqueous nanosuspension comprising nanoparticles as seeding material at a supersaturation level with respect to the substance in the range of 1 and 1000 optionally isolating micro-particles.
Resumen de: WO2026067225A1
Provided are a nano-injection, and a preparation method therefor and a use thereof. The nano-injection has good stability, a controllable particle size, and a narrow particle size distribution range; and the nano-injection can be used for intravenous injection, acts rapidly, can effectively control drug burst release during injection, ensures steady drug release, provides a long duration of action, exhibits an excellent analgesic effect, and offers good safety.
Resumen de: WO2026073266A1
The present disclosure relates to a compound containing two or more hydrophobic chains and a polyacrylate polymer with one or more PEG side chains attached to the carboxylic acid group of the polyacrylate polymer. The compound is further defined by formula I: wherein the variables are as defined below. These compounds may be used in the preparation of lipid nanoparticles for the treatment or prevention of a disease or disorder.
Resumen de: WO2026067584A1
The present application discloses a sirolimus-albumin composition and a preparation method therefor. The preparation method of the present application incorporates an incubation step before solvent removal via evaporation of liquid having undergone high-pressure homogenization, thereby resulting in more uniform nanoparticles and further improving the physical stability of a nanosuspension and the chemical stability of a formulation without the need for any stabilizer. Compared with marketed products, the sirolimus-albumin composition of the present application can be completely dissolved within 1-3 min, the reconstitution operation is simpler, and a nanoparticle suspension after reconstitution remains stable at 30°C for 24 h, thereby offering greater convenience for clinical use. In addition, the composition of the present application can be stored at room temperature, is convenient to transport, and has a longer shelf life.
Resumen de: US20260091127A1
Antimicrobial Janus nanoparticles (NPs) having distinct hydrophobic and polycationic surfaces are embedded in crosslinked polymers. These encapsulated Janus NPs have increased stabilization, to allow for long-term effectiveness. The encapsulated Janus NPs enhance traditional antibiotics and reduce the necessary dosage of those traditional antibiotics to inhibit growth of muti-drug resistant bacteria.
Resumen de: US20260090998A1
The disclosure relates to methods of using block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to methods of using polymer nanoparticles for delivering nucleic acids for treating NF1.
Resumen de: WO2026072616A1
The present disclosure relates to lipid nanoparticle (LNP) compositions including at least one ionizable cationic lipid and Polyinosinic:polycytidylic acid (poly(I:C)), and compositions and formulations incorporating such LNP compositions. The disclosure also provides methods of using these compositions to elicit an immune response, including for the prevention or treatment of infectious diseases.
Resumen de: US20260092134A1
Degradable polymers were synthesized that self-assemble with nucleic acids, proteins, hydrophobic drugs, and other small molecules to form particles that are effective for delivery into a cell, tissue and/or organism either in vitro or in vivo. The presently disclosed polymers demonstrate differential cell-type specificity, an ability to promote endosomal escape to protect the cargos from degradation and enhance delivery to the cytoplasm, and/or bioreducibility, which enables triggered intracellular drug release to be tuned to promote optimal delivery to the target cell type. The presently disclosed materials may be used to treat a wide variety of conditions or diseases, such as cancer, cardiovascular diseases, infectious diseases, and ophthalmic diseases.
Resumen de: WO2026073261A1
The disclosure relates generally to tRNA-based effector molecules (TREMs) formulated in lipid nanoparticles having a non-naturally occurring modification and compositions and methods relating thereto.
Resumen de: WO2026068705A1
The invention relates to a lipid-based nanoparticle comprising an antigen-binding domain covalently linked to a nonglycolsylated Fc domain, and uses thereof.
Resumen de: US20260090997A1
This disclosure relates to lipid nanoparticles comprising nucleic acids encoding therapeutic proteins and uses in treating diseases such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of lipid nanoparticles as reported herein comprising a vector or nucleic acid encoding peptide based anticancer agent.
Resumen de: US20260090991A1
Disclosed are pharmaceutical compositions containing micronized antibodies encapsulated and/or dispersed in polymeric particles for antibody delivery. The judicious identification of (i) a subset of polymers, (ii) polymers with certain average molecular weights, (iii) a subset of antibody loadings, and/or (iv) pre-loading antibody processing, leads to formation of polymeric particles that possess minimal to no initial burst release of micronized antibody at zero time point. The pharmaceutical compositions are formulated for oral, subcutaneous, or percutaneous administration, and are particularly suited for treatment regimens that involve antibody-based therapy.
Resumen de: US20260091126A1
Described herein is the preparation and use of amino acid-modified lipids for delivery of a small interfering RNA (siRNA), mRNA, miRNA, shRNA, or oligonucleotide via formation of lipid nanoparticles (LNPs) comprising the siRNA, mRNA, miRNA, shRNA, or oligonucleotide and the amino acid-modified lipid. Use of the described lipid nanoparticles to silence overexpression of oncogenes is described.
Resumen de: WO2026071602A1
The present invention relates to: a lipid nanoparticle (LNP) composition for producing NK cells or T cells transformed with CAR, wherein the LNP composition for transforming natural killer (NK) cells or T cells is characterized by comprising a nucleic acid and a novel ionizable lipid; CAR-NK cells and CAR-T cells transformed thereby; and uses thereof. According to the present invention, mRNA can be stably delivered into immune cells through the LNP composition, and the transformed NK cells and T cells exhibit high viability and can highly express the target protein CAR.
Resumen de: WO2026072290A1
Variants of the ZF5.3 peptide having Cys substitutions of one or both His residues of the Cys2His2 Zn(II) coordination site, to form Cys3His (CCHC) or Cys4 (AV5.3), respectively, are used in fusions of the peptides with cargo domains, delivery vehicles and delivery methods.
Resumen de: WO2026071633A1
The present invention relates to an inhalable tumor-microenvironment-targeted drug delivery system for treating lung cancer. Specifically, the present invention provides a lipid-polymer hybrid nanoparticle comprising: a poly(lactic-co-glycolic acid) (PLGA) polymer core that encapsulates a first therapeutic agent such as paclitaxel (PTX); and a lipid shell functionalized with pemetrexed (PEM) that performs a dual function as both an anticancer agent and a target ligand. The nanoparticles are directly delivered to the lungs through inhalation, simultaneously target folate receptor alpha (FR-α) of lung cancer cells and folate receptor beta (FR-β) of immunosuppressive tumor-associated macrophages (M2-TAMs) through a PEM ligand, and can repolarize M2-TAMs into an immunoactive M1 phenotype, while exhibiting a direct cancer cell killing effect by PTX and PEM.
Resumen de: WO2026070952A1
The present invention provides a method for producing a compound (1), the method comprising the following step 1a: step 1a for reacting a compound (3) and a compound (4) in a two-phase system containing an organic base, an inorganic base, water, and a water-insoluble organic solvent, thereby obtaining the compound (1). The definitions of the symbols in the formula are as described in the description.
Resumen de: US20260091128A1
In one aspect, a block copolymer described herein comprises a hydrophilic block including oxazoline monomer or oxazine monomer, and a cationic block comprising monomer including a linear or branched polyamine side chain. In another aspect, a polyion complex comprises a block copolymer comprising a hydrophilic block including oxazoline monomer or oxazine monomer, and a cationic block comprising monomer including a linear or branched cationic polyamine side chain, and a negatively charged biomolecular species associated with the block copolymer. The negatively charged biomolecular species can comprise one or more nucleic acids, such as RNA, DNA, and/or other oligonucleotides.
Resumen de: US20260091129A1
Provided are a nanocomposite for targeted degradation of a pathogenic protein, a preparation method therefor, and use thereof, which pertain to the technical field of nanobiological drugs. The nanocomposite for targeted degradation of the pathogenic protein is provided, which comprises a nanocarrier and a protein-targeting binding peptide grafted on the nanocarrier. The nanocarrier is a nanoassembly of maleimide-polyethylene glycol-polylactic acid and cationic lipids; on the other hand, the use of the nanocomposite in the preparation of drugs including an anti-tumor nanodrug and a Huntington's disease inhibiting drug is provided. The nanocomposite can simulate a key receptor protein in a selective autophagy pathway, so that the pathogenic protein to be degraded can be brought into an autophagosome to be degraded by means of an autophagy pathway, thereby effectively solving the problem that PROTACs cannot degrade large-molecular-weight protein aggregates and LYTACs cannot degrade cytoplasmic proteins.
Resumen de: US20260091125A1
The invention provides multifunctional system for the synchronized delivery of distinct immunoglobulins, in particular antibodies and antibody fragments to specific cancerous cells and tissues located outside of the brain. The multifunctional system is based on an inorganic core particle which is conjugated through a first polymeric linker to a first immunoglobulin; through a second polymeric linker to a second immunoglobulin; through a third polymeric linker to a penetration enhancing moiety; and to a fourth, monofunctional capping linker or spacer. Further provided are a process for preparation of the multifunctional system, pharmaceutical compositions comprising the multifunctional system and uses thereof in therapeutic and/or diagnostic methods.
Resumen de: US20260091107A1
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus Infection, preferably a Coronavirus infection.
Resumen de: US20260090957A1
The invention relates to processes for making pharmaceutical aqueous therapeutic particles (AQTP) having stable exterior water clustering with nanosized thickness between 1 to 300 nanometers wherein the AQTP has increased bioavailability when administered to a mammal compared to conventional pharmaceutical drug particles administered to the mammal. The invention relates to an improved process apparatus which is computer controlled, capable of continuous operation with high efficiency so as to make a more consistently acceptable AQTP compared to an previous prototype process apparatus of the Inventors. The invention provides compositions comprising of AQTP which comprise a substance selected from the group consisting of a cannabinoid such as CBD, a cell membrane pore-forming peptide such as PNC-27, a psychoactive drug, a pharmaceutical, a nutraceutical, a mineral, an anion, a cation, a protein, a peptide, an amino acid, a polymer, a vitamin, an antioxidant, a fertilizer, a chemical, a medical use product, a medical kit use product, a personal consumer use product, a manufacturing use product, an energy use product such as a battery, and any combination thereof.
Resumen de: AU2026201855A1
Provided is a polymer comprising a hydrolysable polymer backbone, the polymer backbone comprising (i) monomer units with a side chain comprising a hydrophobic group; (ii) monomer units with a side chain comprising an oligoamine or polyamine; and optionally (iii) monomer units with a side chain comprising an ionizable group, as well as a method of preparing said polymer, and a method of delivering a nucleic acid and/or polypeptide to a cell using the polymer. ar a r
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: AU2026200326A1
Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines. an a n
Resumen de: US20260090989A1
The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
Resumen de: US20260091104A1
The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
Resumen de: WO2026065739A1
Disclosed in the present invention is a short peptide composition for inhibiting inclusion body formation and promoting Gag-Like protein nanoparticle self-assembly, comprising a C-terminus short peptide and an N-terminus short peptide. The amino acid sequence of the N-terminus short peptide is as shown in SEQ ID NO: 1, and the amino acid sequence of the C-terminus short peptide is as shown in SEQ ID NO: 2. The short peptide composition can effectively avoid the formation of an inclusion body of a prokaryotically expressed protein and/or promote the solubilization of the prokaryotically expressed protein. Furthermore, by binding the composition to HIV-1 p24 and human endogenous retrovirus K capsid protein CA, nanoparticles are respectively prepared, which can be used as carriers for antigen surface display or drug delivery. Nanoparticles formed from HIV-1 capsid protein p24 and human HERV K CA both have cavities significantly larger than those of ferritin, leading to a greater loading capacity, and also exhibit good stability and wide applicability as antigen display platforms.
Resumen de: AU2024344058A1
Disclosed are lipidoid compounds having the structure of formula (X) or formula (I): wherein the groups are as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses pharmaceutical compositions comprising a lipidoid composition of the invention.
Resumen de: EP4717708A1
The purpose is to develop a crosslinked collagen hydrogel that can be easily manufactured and has high transparency, high safety, and low toxicity. It was found that a platinum-crosslinked collagen hydrogel that is colorless, transparent, and free of cytotoxicity can be manufactured by incubating collagen of a specific concentration and a platinum(II) complex of a specific concentration under conditions of a specific pH, and the present invention was accomplished. Specifically, the present invention provides a hydrogel that is composed of platinum-crosslinked collagen in which collagen is crosslinked by a platinum(II) complex and exhibits a visible light transmittance of 60% or more when it is measured at an absorbance of 400 nm in a cell having an optical path length of 10 mm.
Resumen de: AU2024250977A1
Provided herein are dispersible powder compositions comprising metal oxide particles and water, as well as methods of preparing dispersible powder compositions.
Resumen de: MX2025013817A
The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating antigens associated with primary biliary cholangitis (PBC), compositions comprising the particles and use thereof for the treatment of PBC.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: CN121758411A
本发明涉及生物医药、基因治疗技术领域，特别是涉及一种可质子化阳离子脂质、核酸递送系统及其应用。本发明所述可质子化阳离子脂质具有如式（I）所示的结构，其末端含有羟基、氨基等可质子化基团。所述可质子化阳离子脂质可形成脂质纳米颗粒，用于包载多种核酸物质。所述脂质纳米颗粒核酸递送系统在体外具有高的细胞转染效率，在体内能靶向递送至肝脏等器官，实现高效的基因编辑。本发明提供的可质子化阳离子脂质所构建的脂质纳米颗粒包封率高、稳定性好、递送效率优异，在基因治疗与细胞工程领域具有广泛应用前景。
Resumen de: CN121754661A
本发明涉及一种载QS‑21的纳米佐剂及其制备方法和应用。本发明的纳米佐剂利用生物可降解聚合物、胆固醇和阳离子脂质包载QS‑21通过O/W方式形成固体脂质颗粒，其具有良好的分散性，且表面带正电荷，可吸附带负电的抗原蛋白以制备纳米佐剂疫苗。本发明的纳米佐剂疫苗中的胆固醇可与QS‑21结合，能够更好的实现QS‑21的包载，提高纳米佐剂疫苗的安全性与稳定性，在预防病毒感染中具有广泛应用前景。
Resumen de: CN121758648A
本发明属于药物制剂、药物递送与疫苗技术领域，涉及一种烷基化香菇多糖的制备方法及其在LNP疫苗中的应用。本发明通过对香菇多糖进行烷基化修饰，使其能够高效溶于LNP中，适于脂质纳米颗粒（LNP）mRNA疫苗的制备。采用本发明的烷基化香菇多糖制备mRNA疫苗，可以将烷基化香菇多糖与mRNA协同装载/组装于同一脂质纳米递送体系,制备成抗原与佐剂一体化的疫苗体系，解决了现有技术中的难题，显著提升抗肿瘤免疫应答的强度与广度，具有高安全性，高效免疫激活，靶向性强的特点，可以广泛用于肿瘤预防/治疗效。
Resumen de: WO2025093037A1
The invention relates to an immunogenic fragment of African swine fever virus p54 protein, a recombinant protein, an immunogenic composition and a use thereof. The provided immunogenic fragment of African swine fever virus p54 protein or a variant thereof with immunogenicity can improve the expression quantity while retaining the strong immunocompetence.
Resumen de: WO2025093039A1
Provided are an immunogenic fragment, a recombinant protein and an immunogenic composition of an African swine fever virus p15 protein and the use thereof. The immunogenic fragment of the African swine fever virus p15 protein or an immunogenic variant thereof has a higher expression level, and the strong immune activity is maintained.
Resumen de: WO2025093041A1
An immunogenic fragment of African swine fever virus CD2v protein, a recombinant protein, an immunogenic composition, and a use thereof. The provided immunogenic fragment of African swine fever virus CD2v protein or a variant thereof with immunogenicity can greatly improve the expression quantity while retaining the strong immunocompetence.
Resumen de: US20260014089A1
The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.
Resumen de: KR20260043575A
본 발명은 특정 조직, 특히 비장 또는 면역 세포에 치료 분자를 정확하게 전달할 수 있는, 지질 나노입자(LNP)에 선택적 장기 표적 지질(Selective Organ Targeting lipid, SORT lipid)을 부가한 조성물에 관한 것으로, 전달 효율 및 체내 안정성이 우수하여 핵산 치료제 관련 기술 분야에 유용하게 사용할 수 있다.
Resumen de: KR20260043180A
본 출원의 과산화효소 모방 효소, 포도당 산화효소 및 광열효과를 갖는 입자를 포함하는 나노 구조체는 암 예방 또는 치료용 약학적 조성물로 활용될 수 있다.
Resumen de: CN121754506A
本发明属于生物医药领域，涉及一种载药纳米囊泡及其制备方法和应用。该载药纳米囊泡包含：囊泡核，其包含能特异性靶向沉默NR1D1基因的siRNA；囊泡膜，其由红细胞膜、巨噬细胞膜、心磷脂、胆固醇与卵磷脂融合而成。该载药纳米囊泡能特异性靶向脓毒症免疫抑制阶段的巨噬细胞，并具有细胞内响应释放功能，其通过抑制NR1D1表达恢复BMAL1及IGF2BP2‑ATP6V1B2/ATP6V0c轴功能，重建巨噬细胞吞噬功能和溶酶体依赖的细菌清除能力，显著提高脓毒症免疫抑制模型动物的生存率并降低细菌载量。相比于传统的电穿孔法，本发明的制备方法显著提高了siRNA的包封率。
Resumen de: CN121754660A
本发明涉及一种载MPLA‑QS‑21的聚合物固体脂质复合纳米佐剂及其制备方法和在病毒感染预防中的应用，该载MPLA‑QS‑21的聚合物脂质复合纳米佐剂为包载MPLA及QS‑21且以聚乳酸类可降解聚合物、胆固醇和阳离子脂质为材料通过O/W方式形成的固体脂质球形纳米颗粒，在该纳米颗粒的表面通过静电吸附的方式携载抗原以形成纳米佐剂疫苗。本发明所涉及的载MPLA‑QS‑21的聚合物固体脂质复合纳米佐剂疫苗可促进抗原提呈细胞的活化，快速激活细胞免疫和体液免疫，分泌高水平的抗体及细胞因子，从而达到有效预防病毒感染性疾病的目的，是增强抗原免疫原性的有效递送系统。
Resumen de: CN121759475A
本发明公开了一种高稳定性mRNA构建体及其制备方法和用途，属于基因治疗技术领域。所述mRNA构建体从5'端到3'端依次包含：5'非翻译区、编码目的蛋白的开放阅读框、翻译增强与稳定元件A7S、3'非翻译区以及分段式Poly(A)尾。其中，所述分段式尾部由多个交替排列的腺苷酸片段和单个胞嘧啶间隔序列组成，且所述3'非翻译区与分段式Poly(A)尾之间不包含长度≥20 nt的连续腺苷酸序列。本发明通过特定分段式Poly(A)尾与A7S元件的协同作用抑制质粒扩增不稳定性并延缓mRNA去腺苷化降解以延长功能性半衰期。本发明提供的构建体及药物组合物可用于制备长效蛋白替代疗法等基因治疗药物。
Resumen de: CN121759492A
本发明涉及治疗性核酸疫苗领域，公开了一种可适用于多种人乳头瘤病毒（HPV）型别感染相关癌前病变和肿瘤的治疗性mRNA疫苗的设计策略。所述mRNA自N端至C端依次编码包括膜导向肽与HPV去致癌化的E6和E7抗原，二者可直接连接或通过1‑20个氨基酸的柔性接头连接。所述mRNA可由多种递送系统递送，疫苗在小鼠模型中诱导强效持久的细胞免疫和体液免疫；该策略适用于多种HPV高危型感染引起的宫颈、阴道、肛门等部位高级别鳞状上皮内病变及恶性肿瘤的治疗。
Resumen de: CN121754500A
本发明公开了一种OMVs@Se生物活性制剂、其制备方法及应用。该制剂通过将硒纳米颗粒包覆于细菌外膜囊泡形成内核‑外壳结构，实现靶向递送至肺部巨噬细胞，有效抑制其铁死亡，并协同调控炎症反应，增强免疫清除能力，从而对细菌性肺炎发挥高效免疫治疗作用。
Resumen de: CN121754503A
本发明公开了一种纳米药物载体的改良装载方法，将重组人重链铁蛋白或其衍生物的载体加至高浓度脲溶液中，混合反应，使重组人重链铁蛋白壳解聚；加入药物，混合孵育；将孵育所得反应液用Tris缓冲溶液稀释到低浓度脲溶液中，反应8‑15h，使重组人重链铁蛋白壳复聚，最后通过Tris缓冲液用截留分子量 50 KD的膜包换液，得到装载完成的铁蛋白药物复合颗粒。本发明通过提供了“稀释后放置再换液，药质比优化”的制备方法，实现了蛋白回收率和载药量均明显提升的效果，蛋白回收率可达100%，载药量可达186 μg/mL。
Resumen de: CN121754505A
本发明公开了一种包埋虾青素的纳米颗粒及其制备方法，属于食品工业技术领域。本发明通过美拉德反应将亲水性的单糖接枝到鳕鱼鱼皮肽链上，使其具有优异的两亲性，而两亲性糖基化鳕鱼鱼皮肽通过疏水相互作用和空间自组装将虾青素包埋于纳米颗粒内部，形成了在内部空腔及特定功能的稳定纳米壳体结构，对疏水性物质虾青素能够高效包埋和递送；经本发明方法制备的对虾青素具有包埋效果的糖基化鳕鱼鱼皮肽，具有纳米级粒径和更大的比表面积，从而具有更高的包封率和装载量，而且具有流体力学直径小的优点，能够提高递送效率，在食品的营养素运输和功能性食品设计等方面有着巨大的应用价值。
Resumen de: CN121754502A
基于微流控混合技术制备壳聚糖‑聚阴离子纳米颗粒的方法及应用，该方法包括：配制水相1为壳聚糖酸性水溶液，配制水相2为聚阴离子水溶液并加入表面活性剂；利用微流控设备及微流控混合器/芯片，使两相按设定总流速与流速比连续注入并在微尺度通道内快速混合，使壳聚糖与聚阴离子静电复合和/或离子交联形成纳米颗粒；对所得分散液过滤以去除凝聚体并收敛粒径分布。所述水相2还可包含阴离子药物或活性成分，优选核酸类物质，以制得负载型纳米颗粒。所得分散液可在0～8℃短期保存，或加入冷冻保护剂后冻干获得粉末。本发明工艺可连续化放大，提升粒径一致性与分散稳性。所述纳米颗粒用于递送所述阴离子药物或活性成分进入细胞或组织。
Resumen de: CN121759472A
本发明公开了一种核酸分子及其应用。所述核酸分子包含编码胰岛素样生长因子结合蛋白‑1的CDS的核酸序列，所述核酸序列如SEQ ID NO:2所示。本发明所述IGFBP‑1 mRNA LNP脂质纳米颗粒能够显著提高IGFBP‑1在外周血（血清）及肿瘤微环境（肿瘤间质液）中的蛋白含量、还能够显著增加CD8+T的抗肿瘤功能；在与肿瘤疫苗联合使用时，也可显著提高肿瘤疫苗的治疗效果，在肿瘤治疗领域具有广阔的应用前景。
Resumen de: CN121759482A
本申请涉及兽药技术领域，具体提供一种用于预防猫传染性腹膜炎的多核苷酸分子组合物、嵌合多核苷酸分子和mRNA疫苗。为克服现有技术中S蛋白全长抗原引发的ADE效应，本申请采用无ADE风险的FIPV N蛋白，并与筛选出的S蛋白特异性T细胞和B细胞表位组合。核心方案包括两类：一是包含编码N蛋白和S蛋白表位肽的分开多核苷酸组合物；二是编码N蛋白与S蛋白表位肽的单一嵌合多核苷酸。这些多核苷酸经密码子优化，并封装于脂质纳米颗粒（LNP）中制成疫苗。实验证明，该疫苗能协同激发强大免疫应答，在不引起ADE的前提下，将免疫猫的生存率从基准的40%显著提升至80%‑100%，有效预防FIP。
Resumen de: KR20260043428A
본 발명은 종양 표적화 표면 개질된 MXene 나노 입자 및 이의 제조 방법에 관한 것으로, 광열제인 MXene에 종양 표적화를 위한 RGD 펩타이드를 결합하여 치료 효율성을 높이고, 나노 크기의 MXene 입자를 이용하여, 투과성 및 광열 치료 효과를 향상시키고, 생체 독성 및 생물 안정성을 높일 수 있다. 또한, RGD 펩타이드가 결합된 표면 개질된 MXene 나노 입자로, 종양 선택성을 부여하여 정상 세포와 구분하여 종양에 우선적으로 부착할 수 있다.
Resumen de: CN121754504A
本发明公开了一种负载miR‑424与氧化铈的植物外囊泡复合体及其制备方法和应用，属于生物医药与纳米材料技术领域。所述复合体包含从葛根中提取的植物外囊泡以及负载于其内部的miR‑424与氧化铈纳米颗粒的复合物。其制备方法主要包括：从葛根中提取植物外囊泡；将氧化铈纳米颗粒与miR‑424按质量比复合；再将所得复合物与植物外囊泡共孵育实现负载。本发明提供的复合体兼具了植物外囊泡良好的生物相容性、miR‑424的基因调控功能以及氧化铈纳米颗粒的抗氧化活性，在低浓度下细胞毒性低，且对巨噬细胞显示较好的摄取倾向。该复合体可用于制备药物，尤其在炎症或氧化应激相关疾病（如脓毒症、急性肺损伤）的预防或治疗中具有应用潜力。
Resumen de: CN121754501A
本发明公开了一种工程化细菌外膜囊泡、其制备方法及应用，工程化细菌外膜囊泡包括细菌外膜囊泡和包覆在所述细菌外膜囊泡表面的DNA‑焦磷酸盐矿化层；所述DNA‑焦磷酸盐矿化层中的DNA含有A2适配体。本发明利用滚环扩增技术，以锚定于OMV表面的环状DNA为模板，在OMV表面原位合成DNA‑焦磷酸盐矿化层，形成一种有机‑无机杂化的智能涂层。该方法充分利用DNA序列的可编辑性，通过设计含A2适配体的模板，使所构建的矿化外层具备精准靶向巨噬细胞表面CD14蛋白的能力，进而驱动巨噬细胞向M1表型极化，在实现高效肿瘤免疫治疗的同时，具有方法简单、高效且生物相容性高的显著优势。
Resumen de: CN121754557A
本发明属于医用材料的技术领域，公开了一种基于金属配位聚合物纳米粒子及其制备与应用。制备方法：1）将聚乙烯吡咯烷酮与铁盐在溶剂中混合，调节pH为8‑9，滴加姜黄素的乙醇溶液，滴加完后继续搅拌，获得铁基姜黄素；2）将单宁酸与铁基姜黄素反应，获得单宁酸配位铁基姜黄素；3）在反应介质中，将聚赖氨酸与单宁酸配位铁基姜黄素的反应，获得金属配位聚合物纳米粒子。本发明的方法简单，纳米粒子的组成成分均为天然材料，具有良好生物相容性，能够保留在生物组织内发挥作用，不会引起其他损伤。本发明的纳米粒子具有较好的抗氧化、抗菌和抗炎作用。所述纳米粒子用于制备治疗细菌性角膜炎或伤口感染的药物。
Resumen de: CN121758745A
本发明涉及一种涉及医药技术领域，具体涉及阳离子聚合物及包含其的药物递送系统和应用。所述阳离子聚合物为含有环状二硫基团修饰的阳离子聚合物PEI，其中所述含有环状二硫基团如式（I）～（III）所示，本发明提供的聚合物能够作为药物载体，尤其是能作为核酸药物的载体，实现了肝外器官组织的靶向递送。
Resumen de: WO2025093042A1
Provided are an immunogenic fragment, a recombinant protein, and an immunogenic composition of the African swine fever virus E248R protein, as well as the use thereof. The immunogenic fragment of the African swine fever virus E248R protein or an immunogenic variant thereof can greatly improve expression levels while retaining strong immunological activity.
Resumen de: WO2025093038A1
The present invention relates to an immunogenic fragment of a p30 protein of an African swine fever virus, a recombinant protein, an immunogenic composition, and a use. The immunogenic fragment of the p30 protein of the African swine fever virus or a variant having immunogenicity can greatly improve the expression quantity, and can also reserve strong immunocompetence.
Resumen de: AU2024289116A1
The present invention relates to a composition comprising a solid carrier, an engineered phenylalanine ammonia lyase or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the engineered phenylalanine ammonia lyase or a fragment thereof by embedding the engineered phenylalanine ammonia lyase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition and uses thereof.
Resumen de: CN121731244A
本发明涉及基因工程药物和疫苗制造领域，特别涉及到一种核酸‑小分子药物共递送系统及其制备方法和应用。本发明所述的核酸‑小分子药物共递送系统以脂质组分为载体，所述载体对药物组分进行包封，所述脂质组分包括阳离子脂质、中性磷脂、胆固醇和PEG‑脂质；所述药物组分包括核酸药物和小分子药物；所述核酸‑小分子药物共递送系统的粒径为50‑300 nm。经实验验证，本申请公开的核酸‑小分子药物共递送系统，在抗炎、免疫调节和抗肿瘤领域具有广阔的应用前景。
Resumen de: CN120570996A
The invention discloses a novel application of emodin and a high-density lipoprotein analogue in preparation of a medicine for treating brain nerve injury, and the high-density lipoprotein analogue comprises apolipoprotein A-1 single mimetic peptide and natural phospholipid. The invention has the advantages of long-term stability and no immunogenicity and organ toxicity risk, thereby providing a clinically convertible solution for precise treatment of nerve injury.
Resumen de: CN121731242A
本发明公开了一种靶向M2型巨噬细胞的共递送脂质纳米粒子及其制备方法和应用，该脂质纳米粒子由可电离阳离子脂质、中性辅助脂质、胆固醇、含有二硫键的PEG化脂质、末端连接有甘露糖的PEG化脂质以及被包封的包含miR‑99b和SIRPα siRNA的核酸药物制备而成，其通过引入DSPE‑S‑S‑PEG3000实现肿瘤微环境谷胱甘肽响应性PEG脱落，并利用DSPE‑PEG2000‑甘露糖实现基于CD206识别的主动靶向，从而高效、特异地将治疗性核酸共递送至M2型肿瘤相关巨噬细胞；本发明的纳米粒子能协同逆转M2巨噬细胞为M1抗肿瘤表型并阻断CD47‑SIRPα“别吃我”信号，有效重塑免疫抑制微环境，在肝细胞癌治疗中展现出卓越的肿瘤靶向能力、抑制肿瘤生长与转移以及促进抗肿瘤免疫应答的效果。
Resumen de: CN121737085A
本公开提供了一种新的核酸酶和使用该核酸酶进行基因编辑和核酸检测的方法。在一些实施方案中，本公开提供了该可编程核酸酶是的应用。本公开还提供了包含该可编程核酸酶的组合物、系统和方法。
Resumen de: CN121731481A
本发明提供了一种磷酸芦可替尼纳米结构脂质载体及其制备方法和应用、磷酸芦可替尼组合物，属于药物制剂技术领域。本发明提供的磷酸芦可替尼纳米结构脂质载体和磷酸芦可替尼组合物，通过固态脂质和液态脂质复配以及引入抗晶化剂，将磷酸芦可替尼包封于由固态脂质和液态脂质构成的纳米结构脂质载体核心内，解决了磷酸芦可替尼的吡唑结构导致的独特析晶问题，具有包封率高、稳定性好的优势。本发明还将磷酸芦可替尼纳米结构脂质载体均匀分散于皮肤病学可接受的基质中，得到包含治疗有效量的磷酸芦可替尼组合物，该组合物表现出显著增强的药物稳定性和皮肤滞留能力，降低系统暴露风险。
Resumen de: CN121731454A
本申请涉及医药技术领域，具体公开了一种治疗关节炎的药物制剂及其制备方法，药物制剂由以下原料制成：雷公藤甲素1‑5重量份、芹菜素苹果酸酯20‑50重量份、三七总皂苷5‑15重量份、甘草酸5‑15重量份和药用多肽0.1‑10重量份。本申请以雷公藤甲素为核心攻击单元，通过引入甘草酸实现主动减毒；加入经苹果酸酯化修饰的芹菜素，在保留其多靶点抗炎活性的同时，彻底解决其生物利用度难题；辅以三七总皂苷改善微循环；并引入药用多肽，对炎症和骨破坏通路进行精准干预。
Resumen de: CN121731245A
本发明属于材料科学与生物医药技术领域，更具体地说是涉及一种载药磁性多孔氧化铝复合材料及其制备方法和应用。本发明将磁性纳米颗粒与多柔比星混合，得到悬浮液；将纳米多孔阳极氧化铝浸于悬浮液，干燥后在表面涂覆壳聚糖溶液，烘干后得到载药磁性多孔氧化铝复合材料。该载药磁性多孔氧化铝复合材料具有磁响应能力和可控门控性能，使药物释放方式由传统的被动扩散转变为外界可调控的按需释放，显著提高了释放过程的时间、空间和剂量精确度。
Resumen de: WO2025046121A1
Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least an ionizable lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the ionizable lipid fraction comprises at least one ionizable glycerol dialkyl glycerol tetraether (GDGT) lipid. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine. In a further aspect, the invention relates to the ionizable GDGT lipids and methods for producing them.
Resumen de: CN121731246A
本发明涉及生物医药技术领域，具体涉及提高姜黄素生物利用率的方法及制剂。本发明通过碱性条件下制备姜黄素溶液/载体溶液，以及优化壁材的组成，形成碱性芯材‑复合壁材‑均质稳定‑喷雾干燥的一体化微囊制剂工艺，可实现姜黄素的高效包埋与稳定递送；制备工艺简单，能耗低，生产成本低，适合大规模生产与应用；本发明提供的姜黄素微胶囊以“蛋白‑环糊精‑姜黄素”三元复合物作为内芯，以麦芽糊精作为壳层，粒径均匀的纳米颗粒，Zeta电位绝对值高，包埋率可高达到97‑99%，载药量达到9‑15%，极大提高姜黄素水溶性、适口性、储存稳定性、生物利用度，扩宽姜黄素在口服制剂的应用范围。
Resumen de: CN121736299A
本发明公开了一种钾离子响应型可聚集金纳米粒及其制备方法,该可聚集金纳米粒由钾离子识别型共聚物接枝在金纳米颗粒表面，所述共聚物的结构式如下：其中，x/(x+y+z)＝0.1～0.3，y/(x+y+z)＝0.1～0.3，z/(x+y+z)＝0.4～0.8，x+y+z＝10～300。该可聚集金纳米粒由钾离子识别型共聚物加入去离子水溶解后，与柠檬酸钠还原法制备的单分散性良好的金纳米颗粒在氮气保护下常温共孵育即得。本发明中的聚合物在识别肿瘤微环境中异常钾离子浓度后由亲水性转为疏水性，金纳米颗粒发生团聚，同时呈现出增强的光声信号及光热效应。制备方法简单，生物相容性良好,可用于不同类别肿瘤治疗。
Resumen de: CN121731243A
本发明公开了一种装载抑癌蛋白mRNA的靶向肿瘤的脂质纳米颗粒的制备方法，其步骤包括：（1）将SM102，DSPC，β‑sitosterol，DMG‑PEG2K，DSPE‑PEG2k‑RGD分别溶于无水乙醇，制成母液；（2）按比例量取各组分的母液，混合配制成有机相；（3）将抑癌蛋白mRNA溶于柠檬酸钠缓冲液中，制成水相；（4）有机相和水相通过微流控反应，合成脂质纳米颗粒。还公开了相应的脂质纳米颗粒及应用。本发明在脂质纳米颗粒中设计具有靶向Integrin αVβ3受体阳性肿瘤细胞的靶向肽，使该纳米颗粒可以精准靶向至Integrin αVβ3受体阳性肿瘤细胞；通过脂质纳米颗粒的成分改造与配方优化，实现脂质纳米颗粒对肿瘤细胞的较高转染效率，最终实现促进肿瘤细胞凋亡的抗肿瘤治疗功效。
Resumen de: CN121737166A
本发明适用于生物医药技术领域，提供了用于预防或治疗乙肝病毒感染的单抗原或多抗原mRNA疫苗及其应用。mRNA编码的蛋白包括乙肝病毒表面抗原和/或乙肝病毒前表面抗原1融合泛HLA‑DR结合表位和人源IgG1 Fc段的融合蛋白（Pan‑HLA‑DR‑epitope‑preS1‑Fc）。将mRNA经过脂质纳米颗粒包裹为递送系统后，制备成单抗原或多抗原mRNA疫苗。该mRNA疫苗制剂能特异性增强针对乙肝病毒表面抗原和/或乙肝病毒前表面抗原1的体液免疫应答和细胞免疫应答，可用于乙型肝炎的预防和治疗；且mRNA疫苗制剂中各成分均可广泛获取，有效降低了疫苗成本、提高疫苗产量，具有良好的实际应用价值。
Resumen de: WO2025049632A1
The present invention relates to lipid nanoparticle (LNP) compositions, and diagnostic or therapeutic polynucleotides, e.g. TERT mRNA, which may be delivered with the LNP compositions in formulations to various tissues and cell types throughout the mammalian body, including stem cells, progenitor cells, germ cells, differentiated cells, or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, spleen cells, hepatocytes, kidney cells and/or bone cells, e.g., for the diagnosis, prevention and/or treatment of conditions or disease.
Resumen de: WO2025045247A1
Provides are artificial nucleic acids, in particular RNA. A composition and kit of parts comprising the same are also provided.
Resumen de: WO2025049579A1
The invention provides intranasal formulation for pulmonary delivery of nanoparticles, compositions, uses, and manufacturing methods thereof. In one aspect, an intranasal formulation for intranasal or intrapulmonary administration includes a viscosity agent, an epithelial adherence agent, and a foaming agent. The viscosity agent may include carboxymethylcellulose, the epithelial adherence agent may include poly-lysine, and the foaming agent may include gelatin hydrolysate.
Resumen de: WO2025045142A1
Disclosed herein are immunogenic compositions having circular RNAs encoding VEGF polypeptides. Related methods for manufacture and therapeutic uses thereof are also provided herein.
Resumen de: WO2025049816A1
A method for inserting a polynucleotide exogenous transgene sequence at a pre- determined endogenous genetic locus in a hose cell genome includes: (i) a donor DNA template including a polynucleotide insert; a 5 '-homology arm; and a 3 '-homology arm. In some embodiments, the 5' homology arm and the 3' homology arm are complementary to the DNA in a target region; and (ii) a ribonucleoprotein complex (RNP) including (1) a Cas nuclease, and at least one small guide RNAs (sgRNA) that is complementary to at least one selected nucleic acid sequence within the pre-determined genetic locus in the host cell genome.
Resumen de: CN121731241A
本发明提供了一种脂质纳米颗粒及其应用，具体地提供了一种基于甾醇化可电离脂质的无胆固醇LNP递送系统。该体系通过分子设计将甾醇基团作为疏水尾部整合至可电离脂质骨架中，形成新型甾醇化可电离脂质，并与辅助脂质、PEG‑脂质自组装形成稳定的三组分LNP。本发明克服了传统四组分LNP依赖胆固醇所导致的肝脏高富集问题，核心脂质显著降低了与载脂蛋白E的亲和力，有效规避ApoE/LDLR介导的肝细胞摄取途径。该LNP在完全无需胆固醇的条件下，同时实现了对mRNA的高包封率和优异稳定性，不仅大幅降低肝脏富集，还提高了对脾脏等肝外组织的靶向性，兼具高转染效率和良好生物相容性，为肝外疾病RNA药物的递送提供了创新平台。
Resumen de: CN121737164A
本发明公开了一种环状RNA及其在鸽毛滴虫疫苗中的应用。该环状RNA包含的编码元件能够编码重组鸽毛滴虫AP33或AP65蛋白。该编码元件具有SEQ ID NO.1或SEQ ID NO.2所示序列或其保守变异型序列。该环状RNA在动物体内可以诱导蛋白表达、产生高水平的抗体，其在应用为鸽毛滴虫疫苗时，不含感染性虫种成分，可在体内降解为核苷酸，不会整合到宿主基因组中，对鸽使用没有风险，并可刺激鸽产生较强的免疫反应，包括体液免疫和细胞免疫，从而有效抵御寄生虫感染，同时疫苗稳定性高，且本发明的疫苗可以通过分子技术大规模制备，生产成本低。
Resumen de: WO2025052244A1
The present disclosure provides a pH-inducible structure-switching non-lamellar lipid nanovector (LNV) comprising: (a) at least one ionizable cationic lipid; (b) at least one phospholipid displaying a critical packing parameter (CPP) value > 1; and (c) at least one non-ionic surfactant displaying a CPP value < 1 at a molar concentration of between 20 % and 50 %, a method of making the LNV, a semi-synthetic extracellular vesicle (ssEV) resulting from the fusion of the LNV with extracellular vesicles at a pH higher than 6 and up to about 10, a kit and a use of the ssEV as a medicament or diagnostic agent.
Resumen de: AU2024288333A1
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by any of the formulae disclosed herein. The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations and pharmaceutical formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.
Resumen de: AU2024307699A1
Disclosed herein is a bioactive polymer for forming a solution and/or hydrogel to stabilise one or more pharmaceutically active agents prior to, during or post-administration, the polymer comprising a first monomer for binding water, a second monomer for imparting mechanical properties to the scaffold; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting phase-transition behaviour. Preferably, the first monomer is OEGMA; the second monomer is PLA/HEMA; the third monomer is NAS; and the fourth monomer is NIPAAm, and the polymer comprises: OEGMA in an amount of from about 1 to about 15 mol%; PLA/HEMA in an amount of from 5 to about 50 mol%; NAS in an amount of from 0 to about 15 mol%; and NIPAAm in an amount of up to about 85 mol%.
Resumen de: AU2024309710A1
Described is a method for the preparation of an aqueous mesoparticle composition comprising a lipophilic compound, comprising the steps of: a. Providing an emulsifier or a blend of emulsifiers in powder form; b. Mixing one or more oils at a temperature above 40°C where all oils have become liquid, wherein said oils differ in melting temperature and which mixture comprises at least a sufficient amount of medium chain triglycerides to enable the composition formed in step g have a partly liquid oil phase at temperatures around about 4°C; c. Adding the hydrophobic or amphiphilic compound in any hydrophobic solvent to the oil mixture; d. Optionally letting the mixture cool down to room temperature; e. Adding the emulsifier powder and water to the oil mixture and letting the mixture emulsify, under optional agitation and heating to 30-40°C; f. Subjecting the emulsified mixture to a sonication and optionally mixing or fluidisation treatment until the average particle size of the mixture remains stable; g. Cooling down the sonicated mixture allowing sufficient time for crystallisation; and h. Optionally, a second sonication treatment while keeping the mixture cold and compositions produced by the above method.
Resumen de: AU2024312860A1
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.
Resumen de: CN121732794A
本发明涉及一种高分散的超顺磁性金磁球形纳米粒子及其制备方法和应用，包括以下步骤：（a）在Fe3O4磁性微球表面包裹上mSiO2壳层得Fe3O4@ mSiO2磁性微球；（b）采用氨基硅烷对所述Fe3O4@ mSiO2磁性微球进行表面修饰；（c）将步骤（b）的产物与过量的金种溶液进行混合，得到Fe3O4@ mSiO2‑Au磁性微球；（d）将所述Fe3O4@ mSiO2‑Au磁性微球于金生长液中进行壳层的生长得到超顺磁性金磁球形纳米粒子。能够获得分散性好、包裹均匀的金磁球形纳米粒子，在不影响纳米粒子磁性的情况下，具有良好的拉曼增强效果。
Resumen de: US20260085120A1
Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-LI or PD-L2 by administering to the patient a nanoparticle composition and a PD-I immunotherapy.
Resumen de: AU2026201692A1
The present invention provides, among other things, methods of formulating nucleic acid- containing nanoparticles with an mRNA encoding an enzyme to afford efficient delivery of payload to a cell or tissue of interest via subcutaneous administration. The resulting payload can be efficiently delivered to the liver and other organs or tissues of a treated subject. ar a r
Resumen de: AU2024355542A1
Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is an LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Resumen de: AU2024345757A1
The present invention relates to oligoglycerol-containing lipids and in particular to cationic or cationizable oligoglycerol-containing lipids and to a method for providing these oligoglycerol-containing lipids. Further, the present invention relates to liposomes, in particular thermosensitive liposomes comprising the novel oligoglycerol-containing lipids. Further the invention relates to liposomes comprising the novel oligoglycerol-containing lipids, which liposomes have an adjustable surface charge.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: AU2024332565A1
The present disclosure provides lipidoid compounds of formulae (I) and (II) and compositions comprising them, methods of preparing such compositions, and the use of these compositions in gene delivery applications.
Resumen de: WO2026061393A1
Provided in the present invention are a lipid nanoparticle used for delivering a nucleic acid molecule that encodes a secretory protein and the use thereof. The lipid nanoparticle can deliver the nucleic acid molecule to the liver for the treatment of liver diseases and other diseases. Also provided in the present invention are a preparation method for the lipid nanoparticle, a pharmaceutical composition comprising the lipid nanoparticle, and the use of the lipid nanoparticle and the pharmaceutical composition in the treatment of diseases.
Resumen de: WO2026060590A1
The present application relates to the technical field of nanocapsules for medical preparations, and particularly relates to dTRIM24 biocompatibility-based anti-atherosclerotic nanoparticles composed of nanoparticles and M1 macrophage membrane vesicles. By using a microfluidic photoporation chip, the nanoparticles are encapsulated by the M1 macrophage membrane vesicles. The nanoparticles are obtained by combining dTRIM24 and Fe3O4 magnetic nanoparticles. The biomimetic nanoparticles of the present application reasonably solve the problems of poor specificity and low efficiency, and have improved anti-atherosclerotic plaque-targeting and biological homology.
Resumen de: AU2024325364A1
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use such as a compound of Formula (A) or a pharmaceutically acceptable salt thereof.
Resumen de: WO2026064512A1
The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.
Resumen de: WO2026064791A1
Described herein are multivalent nanoparticles. In some embodiments, the multivalent nanoparticles contain a programmable stochiometric amount of three or more polypeptides attached to a lipid shell of the multivalent nanoparticles. In some embodiments, one or more of the polypeptides is an antigenic polypeptide. Also described herein are formulations, such as vaccine formulations, that can contain a multivalent nanoparticle described herein. Also described herein are methods of using the multivalent nanoparticles described herein, such as in a vaccine or drug delivery.
Resumen de: WO2026063696A1
The present invention relates to a method for preparing a genetic material delivery nanogel, which is based on a positively charged polymer-naturally derived polymer-phenol compound copolymer, the method comprising the steps of: (1) introducing a carboxylic acid or amine group-containing phenol compound into a naturally derived polymer so as to prepare a naturally derived polymer-phenol compound copolymer, which is amide-bonded and cross-linkable; and (2) introducing a positively charged polymer or material into the naturally derived polymer-phenol compound copolymer of step (1) so as to prepare a positively charged polymer-naturally derived polymer-phenol compound copolymer, which is amide-bonded.
Resumen de: WO2026064744A1
The subject invention provides materials and methods for treating diseases affecting the central nervous system (CNS) and/or other viral reservoir organs utilizing nanoscopic diamond particles, i.e., nanodiamonds (ND), loaded with drug molecules and microglial targeting moiety.
Resumen de: WO2026062291A1
The present invention belongs to the field of biomedicine and drug delivery. The invention relates to LipexSil® lipid-containing nanoparticle ("LNP") compositions, that permit preferential targeting of spleen versus liver, where preferential targeting is defined as a luminescence intensity ratio of spleen and liver greater than 9 after administration of a luminescent cargo, when the different weights of spleen and liver are taken into account. In the LNP composition, a silicon-containing ionizable lipid is combined with a certain structural lipid, a helper lipid, a shield lipid and a fifth lipid component. The invention describes the production and characterization of the lipid nanoparticles and in vivo experiments demonstrating that the corresponding formulations with LipexSil® lipids as described in WO2024/023174 are superior to the current approach, delivering their cargo (e.g. RNA, DNA, mRNA, microRNA, siRNA, ceDNA, pDNA, circular DNA, small biologically active molecules) preferentially to the spleen.
Resumen de: US20260083680A1
A mesoporous nano-magnesium oxide for drug loading and a preparation method thereof are provided. The mesoporous nano-magnesium oxide particle has a particle size of 50 nm to 150 nm, and includes abundant mesoporous structures with a pore size of 2 nm to 20 nm. A surface of the particle has a positive potential in absolute ethanol, with a Zeta potential distribution of 10 mV to 100 mV. The preparation method includes: preparing a mixture of magnesium oxalate and CTAB as a precursor; adding the precursor to a quartz crucible, and placing the quartz crucible in a muffle furnace; calcining at 200°C for 1 h to make the CTAB in the mixture completely decomposed to produce pure magnesium oxalate; and heating to 530°C, and calcining for 1 h to 6 h to make the magnesium oxalate fully decomposed to produce the nano-magnesium oxide microparticle.
Resumen de: WO2026064341A2
Disclosed are polymeric nanoparticles and microparticles having a tunable elastic modulus and having one or more biological proteins conjugated to a surface thereof and their use in immunotherapies for treating diseases, such as cancer or infectious diseases.
Resumen de: US20260083683A1
A protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy, and a manufacture of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) which have higher concentrations of fibrinogen molecules per sphere than FAS, and their use for medical treatments. Both kinds of nanoparticles are effective in the mitigation of the toxic effects of certain chemotherapeutic and radiological agents that are typically used in the treatment of cancer, or the treatment of autoimmune diseases, or for patients with both diseases. FAS and HFS can exert their beneficial effects via a variety of mechanisms which match the need of the body for specific cell types, including any of the subgroups of T cells and antibody producing cells, the relative concentration of each kind is vital to the balance between tumor surveillance and autoimmune disease suppression.
Resumen de: WO2026061537A1
The present invention provides an ionizable lipid compound, and specifically relates to a compound of formula (I'), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof. The present invention also provides a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition comprising same in nucleic acid delivery.
Resumen de: WO2026064752A1
Disclosed are compositions and methods for in vivo genetic engineering of lymphocyte precursors. A lipid nanoparticle (LNP), surface-functionalized for lymphocyte precursor targeting, encapsulates a DNA payload comprising a therapeutic gene flanked by engineered Recombination Signal Sequences (RSS). The RSS spacer incorporates at least one non-natural nucleotide, reducing integration risks. Because RAG1 and RAG2 are expressed only after commitment to the lymphoid lineage, integration is restricted to immune precursors and cannot occur in stem cells or reproductive cells. Upon systemic delivery, the endogenous RAG1/RAG2 complex integrates the payload into the precursor genome. Modified precursors undergo clonal expansion in vivo, amplifying the therapeutic effect from relatively low doses. In certain embodiments, the DNA payload encodes receptors or antibodies that specifically recognize aggregated amyloid proteins, including transthyretin (TTR) fibrils and immunoglobulin light- chain aggregates, enabling therapeutic treatment of amyloidosis. However, the platform is not limited to amyloidosis and can be applied to oncology, infectious diseases, autoimmune disorders, and other protein misfolding conditions.
Resumen de: US20260083835A1
A non-infections bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.
Resumen de: AU2023452365A1
Present disclosure describes a lipid polymer hybrid nanoparticle and a method to synthesize such nanoparticles or such nanoparticle-containing compositions. The nanoparticles are made of biodegradable polymer based micellar core surrounded by lipid-based shell, wherein majority of a pharmaceutical agent is present on the inner periphery of such nanoparticles due to physical adherence with the lipid molecules. Only a minor amount of the pharmaceutical agent is encapsulated in the micellar core. Hence, the lipid-based shell becomes a primary excipient part of the nanoparticle and the biodegradable polymer containing core becomes a secondary excipient part of the nanoparticle.
Resumen de: WO2026060495A1
The present disclosure relates to ionisable lipids of Formula I and related structures that comprise a headgroup, core, and hydrophobic substituents. The lipids are capable of forming lipid particles, including lipid nanoparticles (LNPs), in combination with additional lipids such as neutral lipids, charged lipids, structural lipids, or PEGylated lipids. The lipid particles are suitable for delivery of therapeutic agents, including polynucleotides, peptides, antibodies, and small molecules. Compositions comprising the ionisable lipids and methods of forming and using the lipid particles are also provided.
Resumen de: WO2026062193A1
A method of producing a composition containing a nucleic acid-lipid particle, the method comprising the steps (a) to (d): (a) preparing a first mixture which is a lipid mixture comprising a cationically ionizable lipid in a water-soluble organic solvent; (b) preparing a second mixture in aqueous solution, the second mixture comprising (i) a nucleic acid and (ii) malate buffer; (c) mixing the first mixture with the second mixture to produce an intermediate composition comprising the nucleic acid-lipid particle; and (d) further processing of the intermediate composition by buffer exchange, wherein the buffer used in the buffer exchange comprises tris(hydroxymethyl)-aminomethane (Tris) and/or a pharmaceutically acceptable salt thereof, to produce the composition comprising the nucleic acid-lipid particle; is provided.
Resumen de: WO2026064396A1
Orally administrable nanoparticle complexes of biological molecules and biopolymers are described herein, and include formulations for the oral administration of peptides, proteins, nucleic acids, and antibodies.
Resumen de: WO2026060493A1
The present disclosure relates to ionisable lipids of Formula I and related structures that comprise a headgroup, core, and hydrophobic substituents. The lipids are capable of forming lipid particles, including lipid nanoparticles (LNPs), in combination with additional lipids such as neutral lipids, charged lipids, structural lipids, or PEGylated lipids. The lipid particles are suitable for delivery of therapeutic agents, including polynucleotides, peptides, antibodies, and small molecules. Compositions comprising the ionisable lipids and methods of forming and using the lipid particles are also provided.
Resumen de: WO2026064536A1
The disclosure provides a liposome nanoparticle, a pharmaceutical composition comprising liposome nanoparticles, and a method of treating brain cancer. In some aspects, the liposome nanoparticle comprising a folate bearing lipid and nucleic acid molecules (e.g., siRNA or shRNA) that reduce the expression of H2.0 Like Homeobox (HLX). The liposome nanoparticle optionally comprises a diameter of about 50 nm to about 400 nm. In some aspects, the pharmaceutical composition comprises the liposome nanoparticles and a pharmaceutically acceptable carrier, diluent, or excipient. In some aspects, the method of treating brain cancer comprises administering to a subject in need thereof the liposome nanoparticle.
Resumen de: US20260083681A1
A formulation is provided for a spray dried lipid nanoparticle matrix particles, including lipid nanoparticles, a buffer system, and a barrier matrix stabilizer, wherein the barrier matrix stabilizer is included in a solid weight percent based on a maximum osmolarity and a maximum acceptable injectable volume of an injectable formulation comprising the spray dried lipid nanoparticle matrix particles.
Resumen de: KR20260040948A
본 발명은 미생물 유래 대사물질을 포함하는 지질나노입자에 관한 것으로, 유로리틴 A (Urolithin A; UroA) 및 인돌-3-프로피온산 (indole-3-propionic acid; InD3) 중 어느 하나 이상을 포함하는 지질나노입자의 종양 억제 능력 및 면역 기억 향상 효과가 우수하여 mRNA 백신 및 암 치료제로 이용될 수 있다.
Resumen de: WO2026064250A2
Compositions and methods are provided for inactivating ghrelin in mammalian cells by administration of a polynucleotide encoding a butyrylcholinesterase (BChE) enzyme.
Resumen de: WO2026063749A1
The present invention relates to a novel synthesis method for iodine-based nanoparticles and, more specifically, to iodine-based nanoparticles manufactured by electron beam irradiation, a method for manufacturing same, and a medical use thereof. Unlike conventional chemical synthesis methods, the method for manufacturing iodine-based nanoparticles, according to the present invention, can rapidly mass-produce small- and uniform-sized nanoparticles with a simple synthesis method using electron beam irradiation, and the iodine-based nanoparticles manufactured thereby are loaded with melittin and conjugated with transferrin, and thus can be used as a contrast agent for diagnostic imaging, as a drug delivery platform targeting a transferrin receptor, and as a therapeutic agent capable of treating vascular diseases by delivering drugs such as melittin.
Resumen de: US20260083860A1
Disclosed are methods and compositions for functional genetic modifications at selected sites. Also provided are cell populations, which comprise targeted integration of one or more exogenous polynucleotides, and/or indels at one or more selected gene loci.
Resumen de: US20260085081A1
A phosphatidylamine compound including a plurality of tertiary amino group structures and the composition thereof are provided. The phosphatidylamine compound is a phospholipid compound including two or more tertiary amino group structures, the structure of which is represented by the following formula (I). The compound works together with other lipid components such as cholesterol, DSPC/DOPE, DMG-PEG2000, and other helper lipids to form lipid nanoparticles (LNPs), which may be used for efficient delivery of drug molecules such as nucleic acids (siRNA, mRNA, pDNA), thereby realizing diagnosis and treatment of diseases such as cancer, fibrosis (e.g., liver, lung, kidney).
Resumen de: US20260086085A1
Methods and systems for analyzing lipid nanoparticles using size exclusion chromatograph coupled with multi angle light scattering are disclosed.
Resumen de: US20260083770A1
Disclosed herein are compositions and methods for one step CMC production of RNA therapeutic complexes (nanostructures) that contain nucleoside analogues. In some embodiments, the nucleoside analogues are incorporated into RNA oligonucleotides that self-assemble into an RNA complex during RNA synthesis in a one-step production. Therefore, no additional conjugation or synthesis processes are required.
Resumen de: US20260083673A1
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).
Resumen de: US20260083830A1
The disclosure relates to microparticles and nanoparticles comprising a polymer matrix comprising an uncapped polymer and a net positively charged therapeutic agent at neutral pH. More particularly the disclosure relates to PLGA and/or PLA particles comprising an uncapped polymer for extended, controlled release of positively charged proteins or peptides at neutral pH. Methods of making the particles and administering the particles are also provided.
Resumen de: US20260083682A1
The present invention relates to a kit for construction of drug-containing nanoparticles and a nanoparticle composition for drug delivery. More specifically, the present invention concerns a kit for construction of drug-containing nanoparticles and a nanoparticle composition for drug delivery, each designed to increase the efficiency of cellular drug delivery by utilizing nanoparticles that include a cationic compound and an anionic polymer compound with at least one acidic functional group.
Resumen de: US20260083769A1
The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.
Resumen de: AU2026201779A1
Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle. ar a r
Nº publicación: AU2024357274A1 26/03/2026
Solicitante:
PFIZER INC
PFIZER INC
Resumen de: AU2024357274A1
The invention relates to lipid nanoparticles, immunogenic compositions and methods for use thereof.
BOPI
Sede Electrónica
